<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678561</url>
  </required_header>
  <id_info>
    <org_study_id>A3921038</org_study_id>
    <nct_id>NCT00678561</nct_id>
  </id_info>
  <brief_title>Topical CP-690,550 For Chronic Plaque Psoriasis</brief_title>
  <official_title>PHASE 2A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, INTRA-INDIVIDUAL COMPARISON TRIAL ASSESSING SAFETY, TOLERATION, PHARMACOKINETICS AND PILOT EFFICACY OF 4 WEEKS TREATMENT WITH TOPICAL CP-690,550 IN CHRONIC PLAQUE PSORIASIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study will test effectiveness of an experimental drug applied once or twice daily to two&#xD;
      psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2008</start_date>
  <completion_date type="Actual">July 24, 2009</completion_date>
  <primary_completion_date type="Actual">July 9, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point severity scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Success Based on Physician's Global Assessment (PGA) of Target Lesions</measure>
    <time_frame>Week 4</time_frame>
    <description>PGA of Psoriasis: The investigator scored each target lesion on a 5-point scale, reflecting the erythema, induration and scaling separately for each target lesions. Each parameter was scored from 0 to 4, with appropriate morphologic descriptors. The 5-point scale for PGA was: 0, &quot;clear&quot;; 1, &quot;almost clear&quot;; 2, &quot;mild&quot;; 3, &quot;moderate&quot;; 4 &quot;severe&quot;. The sum of the 3 scores was divided by 3 to obtain a final PGA score. Total score range: 0 to 4, higher score indicated greater severity of disease. Success was considered as PGA response of &quot;clear&quot; and &quot;almost clear&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 1, 2 and 3</measure>
    <time_frame>Baseline, Week 1, 2, 3</time_frame>
    <description>TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Administration Site Adverse Events</measure>
    <time_frame>Baseline up to 7 to 10 days after last dose of study treatment (maximum up to 38 days)</time_frame>
    <description>An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Administration site adverse event included documentation of any clinically significant local reaction, such as erosion, vesicles or scabbing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Plasma Concentrations of CP-690,555</measure>
    <time_frame>0 hour (pre-dose) on Day 14 and 0 hour (pre-dose), 1, 2, 9 hours post-dose on Day 28</time_frame>
    <description>Concentrations below the limit of quantification (LOQ) were not estimable. The LOQ was 0.1 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Biopsy Drug Concentrations</measure>
    <time_frame>Day 28</time_frame>
    <description>Skin biopsy drug concentrations was measured via drug levels in dermis and expressed as nanogram of drug per milligram (mg) of dermis weight. Tissue concentration (ng/mg) = (ng drug/mL extraction solvent multiplied by mL extraction solvent) divided by mg tissue weight; 1 mL of extraction solvent was used.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>2% CP-690,550 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2% CP-690,550 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.02% CP-690,550 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2% CP-690,550 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2% CP-690,550 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.02% CP-690,550 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Vehicle QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Vehicle BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Topical treatment once daily for 28 days</description>
    <arm_group_label>2% CP-690,550 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Topical treatment once daily for 28 days</description>
    <arm_group_label>0.2% CP-690,550 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Topical treatment once daily for 28 days</description>
    <arm_group_label>0.02% CP-690,550 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Topical treatment twice daily for 28 days</description>
    <arm_group_label>2% CP-690,550 BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Topical treatment twice daily for 28 days</description>
    <arm_group_label>0.2% CP-690,550 BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Topical treatment twice daily for 28 days</description>
    <arm_group_label>0.02% CP-690,550 BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Vehicle</intervention_name>
    <description>Topical treatment once daily for 28 days</description>
    <arm_group_label>Placebo Vehicle QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Vehicle</intervention_name>
    <description>Topical treatment twice daily for 28 days</description>
    <arm_group_label>Placebo Vehicle BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having chronic plaque psoriasis for at least 6 months&#xD;
&#xD;
          -  Able to withdraw all prior psoriasis treatments&#xD;
&#xD;
          -  Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or&#xD;
             other ultraviolet light sources during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of active, latent, or inadequately treated infection with Mycobacterium&#xD;
             tuberculosis&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Unwilling to use appropriate contraceptive methods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RUSH University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432-3134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology, PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Imaging Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guildford Dermatology Specialists</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewLab Clinical Research Inc.</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K.Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec metropolitain</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921038&amp;StudyName=Topical%20CP-690%2C550%20For%20Chronic%20Plaque%20Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 13, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <results_first_submitted>December 4, 2020</results_first_submitted>
  <results_first_submitted_qc>December 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <disposition_first_submitted>August 24, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 12, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 23, 2010</disposition_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic plaque psoriasis</keyword>
  <keyword>topical treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>During the study, enrollment into the 4 once daily dosing regimen treatment groups was discontinued in order to decrease the overall total number of participants to be enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2% CP-690,550 Once Daily</title>
          <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="P2">
          <title>0.2% CP-690,550 Once Daily</title>
          <description>CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="P3">
          <title>0.02% CP-690,550 Once Daily</title>
          <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Once Daily</title>
          <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28.</description>
        </group>
        <group group_id="P5">
          <title>2% CP-690,550 Twice Daily</title>
          <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="P6">
          <title>0.2% CP-690,550 Twice Daily</title>
          <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="P7">
          <title>0.02% CP-690,550 Twice Daily</title>
          <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="P8">
          <title>Placebo Twice Daily</title>
          <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2% CP-690,550 Once Daily</title>
          <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="B2">
          <title>0.2% CP-690,550 Once Daily</title>
          <description>CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="B3">
          <title>0.02% CP-690,550 Once Daily</title>
          <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Once Daily</title>
          <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28.</description>
        </group>
        <group group_id="B5">
          <title>2% CP-690,550 Twice Daily</title>
          <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="B6">
          <title>0.2% CP-690,550 Twice Daily</title>
          <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="B7">
          <title>0.02% CP-690,550 Twice Daily</title>
          <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="B8">
          <title>Placebo Twice Daily</title>
          <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="17"/>
            <count group_id="B6" value="17"/>
            <count group_id="B7" value="15"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="7.3"/>
                    <measurement group_id="B2" value="45.7" spread="11.6"/>
                    <measurement group_id="B3" value="50.3" spread="17.0"/>
                    <measurement group_id="B4" value="52.5" spread="13.1"/>
                    <measurement group_id="B5" value="45.9" spread="10.5"/>
                    <measurement group_id="B6" value="43.2" spread="15.8"/>
                    <measurement group_id="B7" value="47.4" spread="13.0"/>
                    <measurement group_id="B8" value="41.1" spread="17.0"/>
                    <measurement group_id="B9" value="46.3" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4</title>
        <description>TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point severity scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Full analysis set (FAS) population included all randomized participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy parameter. N (number of participants analyzed) is signifying those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Once Daily</title>
            <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O2">
            <title>0.2% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>0.02% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Once Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas once daily up to Day 28.</description>
          </group>
          <group group_id="O5">
            <title>2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>0.2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2) gel applied topically on 1 target plaque area, along with matching placebo gel on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O7">
            <title>0.02% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Twice Daily</title>
            <description>Matching placebo gel applied topically on 2 target plaque areas twice daily up to Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4</title>
          <description>TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point severity scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease.</description>
          <population>Full analysis set (FAS) population included all randomized participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy parameter. N (number of participants analyzed) is signifying those participants who were evaluable for this measure.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="5.83"/>
                    <measurement group_id="O2" value="-4.76" spread="11.66"/>
                    <measurement group_id="O3" value="2.48" spread="11.50"/>
                    <measurement group_id="O4" value="-4.17" spread="8.33"/>
                    <measurement group_id="O5" value="-4.46" spread="9.23"/>
                    <measurement group_id="O6" value="-1.77" spread="20.87"/>
                    <measurement group_id="O7" value="-3.29" spread="21.34"/>
                    <measurement group_id="O8" value="-7.14" spread="20.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Success Based on Physician's Global Assessment (PGA) of Target Lesions</title>
        <description>PGA of Psoriasis: The investigator scored each target lesion on a 5-point scale, reflecting the erythema, induration and scaling separately for each target lesions. Each parameter was scored from 0 to 4, with appropriate morphologic descriptors. The 5-point scale for PGA was: 0, &quot;clear&quot;; 1, &quot;almost clear&quot;; 2, &quot;mild&quot;; 3, &quot;moderate&quot;; 4 &quot;severe&quot;. The sum of the 3 scores was divided by 3 to obtain a final PGA score. Total score range: 0 to 4, higher score indicated greater severity of disease. Success was considered as PGA response of &quot;clear&quot; and &quot;almost clear&quot;.</description>
        <time_frame>Week 4</time_frame>
        <population>FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment. N (number of participants analyzed) is signifying those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Once Daily</title>
            <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O2">
            <title>0.2% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>0.02% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Once Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28.</description>
          </group>
          <group group_id="O5">
            <title>2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>0.2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O7">
            <title>0.02% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Twice Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Success Based on Physician's Global Assessment (PGA) of Target Lesions</title>
          <description>PGA of Psoriasis: The investigator scored each target lesion on a 5-point scale, reflecting the erythema, induration and scaling separately for each target lesions. Each parameter was scored from 0 to 4, with appropriate morphologic descriptors. The 5-point scale for PGA was: 0, &quot;clear&quot;; 1, &quot;almost clear&quot;; 2, &quot;mild&quot;; 3, &quot;moderate&quot;; 4 &quot;severe&quot;. The sum of the 3 scores was divided by 3 to obtain a final PGA score. Total score range: 0 to 4, higher score indicated greater severity of disease. Success was considered as PGA response of &quot;clear&quot; and &quot;almost clear&quot;.</description>
          <population>FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment. N (number of participants analyzed) is signifying those participants who were evaluable for this measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active, Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="6.7"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active, Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="13.3"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vehicle, Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vehicle, Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="26.7"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="13.3"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 1, 2 and 3</title>
        <description>TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease.</description>
        <time_frame>Baseline, Week 1, 2, 3</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication; had a valid baseline with at least 1 valid post-baseline efficacy assessment. Here 'N' (number of participants analyzed)= participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Once Daily</title>
            <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O2">
            <title>0.2% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>0.02% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Once Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28.</description>
          </group>
          <group group_id="O5">
            <title>2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>0.2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O7">
            <title>0.02% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Twice Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 1, 2 and 3</title>
          <description>TPSS: all target lesions were scored individually by the investigator for signs of induration, scaling, and erythema. For large target lesions only a portion of the lesion was treated and only the treated portion was rated. Each of the 3 signs was rated on a 5-point scale: 0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = very marked. Total score range for TPSS was 0 to 12, higher score indicated greater severity of disease.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication; had a valid baseline with at least 1 valid post-baseline efficacy assessment. Here 'N' (number of participants analyzed)= participants who were evaluable for this measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="5.56" spread="13.61"/>
                    <measurement group_id="O3" value="-1.39" spread="9.74"/>
                    <measurement group_id="O4" value="-16.67" spread="33.33"/>
                    <measurement group_id="O5" value="-1.59" spread="28.97"/>
                    <measurement group_id="O6" value="4.24" spread="16.30"/>
                    <measurement group_id="O7" value="2.13" spread="11.59"/>
                    <measurement group_id="O8" value="-3.87" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" spread="8.61"/>
                    <measurement group_id="O2" value="0.93" spread="8.90"/>
                    <measurement group_id="O3" value="0.69" spread="8.63"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="-3.49" spread="16.24"/>
                    <measurement group_id="O6" value="0.25" spread="9.82"/>
                    <measurement group_id="O7" value="-4.55" spread="16.11"/>
                    <measurement group_id="O8" value="-4.42" spread="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="2.78" spread="6.80"/>
                    <measurement group_id="O3" value="8.73" spread="13.52"/>
                    <measurement group_id="O4" value="-16.67" spread="28.87"/>
                    <measurement group_id="O5" value="-4.66" spread="13.47"/>
                    <measurement group_id="O6" value="3.06" spread="22.74"/>
                    <measurement group_id="O7" value="-2.99" spread="16.38"/>
                    <measurement group_id="O8" value="-2.83" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Administration Site Adverse Events</title>
        <description>An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Administration site adverse event included documentation of any clinically significant local reaction, such as erosion, vesicles or scabbing.</description>
        <time_frame>Baseline up to 7 to 10 days after last dose of study treatment (maximum up to 38 days)</time_frame>
        <population>FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Once Daily</title>
            <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O2">
            <title>0.2% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>0.02% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Once Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28.</description>
          </group>
          <group group_id="O5">
            <title>2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>0.2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O7">
            <title>0.02% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Twice Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Administration Site Adverse Events</title>
          <description>An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Administration site adverse event included documentation of any clinically significant local reaction, such as erosion, vesicles or scabbing.</description>
          <population>FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vehicle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Plasma Concentrations of CP-690,555</title>
        <description>Concentrations below the limit of quantification (LOQ) were not estimable. The LOQ was 0.1 ng/mL.</description>
        <time_frame>0 hour (pre-dose) on Day 14 and 0 hour (pre-dose), 1, 2, 9 hours post-dose on Day 28</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication; had a valid baseline with at least 1 valid post-baseline efficacy assessment of CP-690,550. Participants of reporting groups 2%, 0.2% and 0.02% CP-690,550 Once Daily regimen had no post-baseline measurable concentration of CP-690,550. &quot;Overall number of participants analyzed&quot; = who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O2">
            <title>0.2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>0.02% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Plasma Concentrations of CP-690,555</title>
          <description>Concentrations below the limit of quantification (LOQ) were not estimable. The LOQ was 0.1 ng/mL.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication; had a valid baseline with at least 1 valid post-baseline efficacy assessment of CP-690,550. Participants of reporting groups 2%, 0.2% and 0.02% CP-690,550 Once Daily regimen had no post-baseline measurable concentration of CP-690,550. &quot;Overall number of participants analyzed&quot; = who were evaluable for this measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.183" spread="0.054"/>
                    <measurement group_id="O2" value="0.116" spread="0.020"/>
                    <measurement group_id="O3" value="NA" spread="NA">Mean and standard deviation were not estimable as data was below LOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.174" spread="0.046"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and standard deviation were not estimable as data was below LOQ.</measurement>
                    <measurement group_id="O3" value="0.126" spread="NA">Standard deviation not calculated as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.191" spread="0.059"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and standard deviation were not estimable as data was below LOQ.</measurement>
                    <measurement group_id="O3" value="0.115" spread="NA">Standard deviation not calculated as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.160" spread="0.039"/>
                    <measurement group_id="O2" value="NA" spread="NA">Mean and standard deviation were not estimable as data was below LOQ.</measurement>
                    <measurement group_id="O3" value="0.102" spread="NA">Standard deviation not calculated as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Biopsy Drug Concentrations</title>
        <description>Skin biopsy drug concentrations was measured via drug levels in dermis and expressed as nanogram of drug per milligram (mg) of dermis weight. Tissue concentration (ng/mg) = (ng drug/mL extraction solvent multiplied by mL extraction solvent) divided by mg tissue weight; 1 mL of extraction solvent was used.</description>
        <time_frame>Day 28</time_frame>
        <population>FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment. Overall number of participants analyzed = participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Once Daily</title>
            <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O2">
            <title>0.2% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>0.02% CP-690,550 Once Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Once Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28.</description>
          </group>
          <group group_id="O5">
            <title>2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>0.2% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O7">
            <title>0.02% CP-690,550 Twice Daily</title>
            <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Twice Daily</title>
            <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Biopsy Drug Concentrations</title>
          <description>Skin biopsy drug concentrations was measured via drug levels in dermis and expressed as nanogram of drug per milligram (mg) of dermis weight. Tissue concentration (ng/mg) = (ng drug/mL extraction solvent multiplied by mL extraction solvent) divided by mg tissue weight; 1 mL of extraction solvent was used.</description>
          <population>FAS population included participants who received at least 1 dose of study medication and had a valid baseline with at least one valid post-baseline value for efficacy assessment. Overall number of participants analyzed = participants who were evaluable for this measure.</population>
          <units>ng/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4145" spread="2.9877"/>
                    <measurement group_id="O2" value="2.2320" spread="2.7257"/>
                    <measurement group_id="O3" value="0.3242" spread="0.6343"/>
                    <measurement group_id="O4" value="0" spread="NA">Standard deviation was not estimable as only 1 participant was evaluable</measurement>
                    <measurement group_id="O5" value="8.2810" spread="10.270"/>
                    <measurement group_id="O6" value="0.2957" spread="0.3675"/>
                    <measurement group_id="O7" value="0.0847" spread="0.1252"/>
                    <measurement group_id="O8" value="0" spread="NA">Standard deviation was not estimable as only 2 participants were evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>2% CP-690,550 Once Daily</title>
          <description>CP-690,550 2.0 percent (%) (50 microgram per square centimeter [mcg/cm^2]) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="E2">
          <title>0.2% CP-690,550 Once Daily</title>
          <description>CP-690,550 0.2% (5 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="E3">
          <title>0.02% CP-690,550 Once Daily</title>
          <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active), applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, once daily up to Day 28.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Once Daily</title>
          <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas, once daily up to Day 28.</description>
        </group>
        <group group_id="E5">
          <title>2% CP-690,550 Twice Daily</title>
          <description>CP-690,550 2.0% (50 mcg/cm^2), gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="E6">
          <title>0.2% CP-690,550 Twice Daily</title>
          <description>CP-690,550 0.2% (5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="E7">
          <title>0.02% CP-690,550 Twice Daily</title>
          <description>CP-690,550 0.02% (0.5 mcg/cm^2) gel (active) applied topically on 1 target plaque area, along with matching placebo vehicle on another target plaque area, twice daily up to Day 28.</description>
        </group>
        <group group_id="E8">
          <title>Placebo Twice Daily</title>
          <description>CP-690,550 matching placebo vehicle applied topically on 2 target plaque areas twice daily up to Day 28.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

